Component

Leu-Gly-Gly peptide

Competitive ACE inhibitor from simulated digestion of nattokinase.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The Leu-Gly-Gly peptide identified from simulated digestion inhibited ACE competitively with an IC50 of 10.78 micromolar.

    Experimental context and source evidence
    duration
    Not stated here
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    In vitro simulated digestion
    exposure
    LGG peptide
    limitations
    An IC50 against purified ACE. Docking and network-pharmacology analyses in the same report are modelling, not measurement.
    organism
    In vitro simulated digestion
    plain_language
    The Leu-Gly-Gly peptide identified from simulated digestion inhibited ACE competitively with an IC50 of 10.78 micromolar.
    primary_references
    Identification and mechanistic characterization of novel ACE-inhibitory peptides derived from Nattokinase. (2026) https://pubmed.ncbi.nlm.nih.gov/41844106/ DOI: 10.1016/j.foodchem.2026.148875
    route
    In vitro
    tissue
    ACE inhibition kinetics with molecular docking

    Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 719–719

    Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · In vitro simulated digestion · source_derived_draft · unverified_draft

    The Leu-Gly-Gly peptide identified from simulated digestion inhibited ACE competitively with an IC50 of 10.78 micromolar.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards